Dry Eye Disease Market

By Drug Type;

Tear-Stimulating Drugs, Topical Corticosteroids, Immunosuppressive Drugs, Artificial Tears, and Others

By Formulation Type;

Liquid and Gel

By Mode of Administration;

Oral and Topical.

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies, Specialty Clinics, e-commerce, and Others.

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn125797569 Published Date: June, 2025 Updated Date: July, 2025

Dry Eye Disease Market Overview

Dry Eye Disease Market (USD Million)

Dry Eye Disease Market was valued at USD 5,792.78 million in the year 2024. The size of this market is expected to increase to USD 8,580.19 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.8%.


Dry Eye Disease Market

*Market size in USD million

CAGR 5.8 %


Study Period2025 - 2031
Base Year2024
CAGR (%)5.8 %
Market Size (2024)USD 5,792.78 Million
Market Size (2031)USD 8,580.19 Million
Market ConcentrationMedium
Report Pages371
5,792.78
2024
8,580.19
2031

Major Players

  • Allergan Plc
  • Novartis AG
  • Otsuka Pharmaceutical Co.,Ltd.
  • Takeda Pharmaceutical Company Ltd (Shire Plc)
  • Santen Pharmaceutical Co Ltd
  • Bausch Health Companies Inc.
  • Akorn, Inc
  • Thea Pharmaceuticals Limited

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Dry Eye Disease Market

Fragmented - Highly competitive market without dominant players


The Dry Eye Disease Market is expanding rapidly as ocular discomfort becomes increasingly common across all age groups. Close to 30% of individuals over 50 now report symptoms of chronic dry eye, fueling the need for targeted medical intervention. Contributing factors such as prolonged digital device usage and lifestyle shifts are worsening tear film instability and eye surface damage.

Shift Toward Innovative Treatment Modalities
Conventional lubricating drops are no longer meeting patient expectations, with 40% expressing dissatisfaction. In response, the industry is embracing advanced therapeutic solutions like biologics and regenerative treatments that target the inflammatory root of dry eye. These next-generation therapies are driving improved symptom resolution and longer-lasting relief.

Smarter Diagnostics Reshaping Eye Care
Technological advancements are reshaping dry eye diagnostics, with 35% of clinics integrating smart diagnostic tools such as NITBUT and meibography. These tools enable earlier and more precise detection, offering tailored treatment plans and effective monitoring over time. Diagnostic innovation is playing a pivotal role in early-stage management and patient outcomes.

Awareness Campaigns Encouraging Early Action
A surge in public awareness efforts has resulted in a 45% increase in patient visits for dry eye evaluation. Educational outreach is empowering individuals to recognize symptoms and seek timely care. Greater understanding of environmental triggers and systemic causes has led to proactive consultation and improved patient compliance.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Type
    2. Market Snapshot, By Formulation Type
    3. Market Snapshot, By Mode of Administration
    4. Market Snapshot, By Distribution Channel
    5. Market Snapshot, By Region
  4. Dry Eye Disease Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Aging Population
        2. Increased Screen Time
        3. Technological Advancements
        4. Rising Awareness
      2. Restraints
        1. Side Effects of Treatments
        2. Lack of Insurance Coverage
        3. Underdiagnosis
      3. Opportunities
        1. Innovations in Drug Delivery Systems
        2. Collaboration and Partnerships in R&D
        3. Personalized Medicine Approaches
        4. Telemedicine and Online Consultations
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Dry Eye Disease Market, By Drug Type, 2021 - 2031 (USD Million)
      1. Tear-stimulating drugs
      2. Topical Corticosteroids
      3. Immunosuppressive drugs
      4. Artificial Tears
      5. Others
    2. Dry Eye Disease Market, By Formulation Type, 2021 - 2031 (USD Million)

      1. Liquid

      2. Gel

    3. Dry Eye Disease Market, By Mode of Administration, 2021 - 2031 (USD Million)
      1. Oral
      2. Topical
    4. Dry Eye Disease Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital pharmacies
      2. Retail pharmacies
      3. Specialty clinics
      4. e-commerce
      5. Others
    5. Dry Eye Disease Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape Analysis
    1. Company Profiles
      1. Allergan Plc
      2. Novartis AG
      3. Otsuka Pharmaceutical Co.,Ltd.
      4. Takeda Pharmaceutical Company Ltd (Shire Plc)
      5. Santen Pharmaceutical Co Ltd
      6. Bausch Health Companies Inc.
      7. Akorn, Inc
      8. Thea Pharmaceuticals Limited
  7. Analyst Views
  8. Future Outlook of the Market